Press Release: Sanofi’s half-year financial report for 2026
Sanofi’s half-year financial report for 2026 Paris, July 30, 2026. Sanofi announces that its half-year financial report for…
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026.…
WORLDLINE : Worldline’s partnership with Crédit Agricole is evolving – Press release
Press Release Paris La Défense, Montrouge, 30 June, 2026 Worldline’s partnership with Crédit Agricole is evolving with the…
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its…
Israel releases classified documents detailing 1976 Entebbe raid to free more than 100 hostages
JERUSALEM — Israel on Friday released a cache of previously classified documents that outline in detail the decisions behind a…
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 25, 2026. The Sanofi Foundation is opening a new…
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without…
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi appoints Paulo Fontoura as Global Head of R&D Paris, June 22, 2026. Sanofi today announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of…
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including…
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3…
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa…
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28,…